---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-24-000143"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2024-12-03T23:59:59+00:00"
generated_at: "2026-05-29T09:43:44.491509+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cartesian announces positive updated Phase 2b data for Descartes-08 in MG; Phase 3 AURORA on track for H1 2025

## Summary
- Descartes-08 showed 5.5-point average MG-ADL reduction at Month 4 (n=12); 33% reached minimum symptom expression at Month 6.
- Responses durable through Month 12: 80% (4/5) maintained clinically meaningful improvement.
- No CRS or ICANS reported; safety supports outpatient administration without lymphodepleting chemo.
- Phase 3 AURORA trial (n≈100) to begin H1 2025; primary endpoint: ≥3-point MG-ADL improvement vs placebo at Month 4.
- Retreated Phase 2a patients showed rapid responses again; no new safety signals.

## SEC filing metadata
- accession: 0001453687-24-000143
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2024-12-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368724000143/0001453687-24-000143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368724000143/rnac-20241203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-24-000143
- JSON: https://secwatch.observer/filing/0001453687-24-000143.json
- Plain text: https://secwatch.observer/filing/0001453687-24-000143.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.